Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
Recruiting · NCT05707819 · Registry updated 2023-02-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Recruiting | Not stated | 2023-02-01 | NCT05707819 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cancer Hospital of Guangxi Medical University | 22 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Guangxi Medical University Cancer Hospital | Nanning | China | 24 |